Intech Biopharm Corporation (TPEX:6461)
Taiwan
· Delayed Price · Currency is TWD 18.00
-0.05 (-0.28%)
Apr 29, 2026, 1:17 PM CST
Intech Biopharm Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -389.03 | -368.21 | -337.99 | -327.88 | -301.76 | Upgrade
|
| Depreciation & Amortization | 90.18 | 86.33 | 84.73 | 85.28 | 85.16 | Upgrade
|
| Other Amortization | 1.09 | 1.02 | 0.09 | 0.08 | 0.14 | Upgrade
|
| Loss (Gain) From Sale of Investments | 0.03 | 0.38 | -0.28 | -0.93 | -0.3 | Upgrade
|
| Stock-Based Compensation | 15.76 | 14.64 | 14.13 | 16.89 | 10.64 | Upgrade
|
| Other Operating Activities | 39.25 | 28.02 | 29.92 | 22.59 | 20.05 | Upgrade
|
| Change in Accounts Receivable | 4.87 | -6.15 | 0.56 | 11.38 | -10.28 | Upgrade
|
| Change in Inventory | -54.92 | -22.61 | 9.36 | 6.55 | -4.27 | Upgrade
|
| Change in Accounts Payable | -5.92 | 9.51 | -1.02 | -1.08 | 1.39 | Upgrade
|
| Change in Unearned Revenue | -64.93 | 5.83 | 2.58 | -0.69 | -2.21 | Upgrade
|
| Change in Other Net Operating Assets | 2.51 | -17.97 | -6.21 | -2.59 | 0.84 | Upgrade
|
| Operating Cash Flow | -361.13 | -269.22 | -204.13 | -190.39 | -200.61 | Upgrade
|
| Capital Expenditures | -61.89 | -43.62 | -30.04 | -10.74 | -21.31 | Upgrade
|
| Sale (Purchase) of Intangibles | -2.12 | - | -0.17 | -0.26 | - | Upgrade
|
| Investment in Securities | -137.5 | 460 | -210 | -195 | -15 | Upgrade
|
| Other Investing Activities | 4.03 | 6 | 4.23 | 2.02 | 0.79 | Upgrade
|
| Investing Cash Flow | -197.48 | 422.37 | -235.98 | -203.98 | -35.52 | Upgrade
|
| Short-Term Debt Issued | 80 | - | - | - | - | Upgrade
|
| Long-Term Debt Issued | - | 2.01 | 27 | 270 | - | Upgrade
|
| Total Debt Issued | 80 | 2.01 | 27 | 270 | - | Upgrade
|
| Short-Term Debt Repaid | -80 | - | - | - | -30 | Upgrade
|
| Long-Term Debt Repaid | -24.19 | -2 | -2 | -15.1 | - | Upgrade
|
| Total Debt Repaid | -104.19 | -2 | -2 | -15.1 | -30 | Upgrade
|
| Net Debt Issued (Repaid) | -24.19 | 0.01 | 25 | 254.9 | -30 | Upgrade
|
| Issuance of Common Stock | 433.91 | - | 460 | 5.06 | 300 | Upgrade
|
| Other Financing Activities | -32.44 | -32.44 | -31.98 | -21.26 | -18.08 | Upgrade
|
| Financing Cash Flow | 377.28 | -32.43 | 453.02 | 238.71 | 251.92 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.52 | 0.2 | 0 | -0 | -0 | Upgrade
|
| Net Cash Flow | -181.85 | 120.92 | 12.91 | -155.66 | 15.8 | Upgrade
|
| Free Cash Flow | -423.02 | -312.84 | -234.17 | -201.13 | -221.91 | Upgrade
|
| Free Cash Flow Margin | -393.41% | -786.44% | -905.98% | -850.56% | -570.48% | Upgrade
|
| Free Cash Flow Per Share | -2.79 | -2.28 | -1.94 | -1.73 | -2.18 | Upgrade
|
| Cash Interest Paid | 32.36 | 32.51 | 32.18 | 21.68 | 18.2 | Upgrade
|
| Cash Income Tax Paid | -0.02 | 0.46 | 0.22 | 0.03 | -0 | Upgrade
|
| Levered Free Cash Flow | -330.52 | -206.2 | -150.09 | -108.35 | -137.16 | Upgrade
|
| Unlevered Free Cash Flow | -309.57 | -184.85 | -129.1 | -93.95 | -124.95 | Upgrade
|
| Change in Working Capital | -118.4 | -31.4 | 5.28 | 13.58 | -14.53 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.